A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis.

TitleA Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis.
Publication TypeJournal Article
Year of Publication2008
AuthorsPhilippar, U, Roussos, ET, Oser, M, Yamaguchi, H, Kim, H-D, Giampieri, S, Wang, Y, Goswami, S, Wyckoff, JB, Lauffenburger, DA, Sahai, E, Condeelis, JS, Gertler, FB
JournalDev Cell
Volume15
Issue6
Pagination813-28
Date Published2008 Dec
ISSN1878-1551
KeywordsAlternative Splicing, Animals, Carcinoma, Cell Movement, Epidermal Growth Factor, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms, Macrophages, Mice, Microfilament Proteins, Models, Biological, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Protein Isoforms
Abstract

The spread of cancer during metastatic disease requires that tumor cells subvert normal regulatory networks governing cell motility to invade surrounding tissues and migrate toward blood and lymphatic vessels. Enabled (Ena)/vasodilator-stimulated phosphoprotein (VASP) proteins regulate cell motility by controlling the geometry of assembling actin networks. Mena, an Ena/VASP protein, is upregulated in the invasive subpopulation of breast cancer cells. In addition, Mena is alternately spliced to produce an invasion isoform, Mena(INV). Here we show that Mena and Mena(INV) promote carcinoma cell motility and invasiveness in vivo and in vitro, and increase lung metastasis. Mena and Mena(INV) potentiate epidermal growth factor (EGF)-induced membrane protrusion and increase the matrix degradation activity of tumor cells. Interestingly, Mena(INV) is significantly more effective than Mena in driving metastases and sensitizing cells to EGF-dependent invasion and protrusion. Upregulation of Mena(INV) could therefore enable tumor cells to invade in response to otherwise benign EGF stimulus levels.

DOI10.1016/j.devcel.2008.09.003
Alternate JournalDev. Cell
PubMed ID19081071
PubMed Central IDPMC2637261
Grant List1-U54-CA112967 / CA / NCI NIH HHS / United States
CA100324 / CA / NCI NIH HHS / United States
GM38511 / GM / NIGMS NIH HHS / United States
GM58801 / GM / NIGMS NIH HHS / United States
P01 CA100324-01 / CA / NCI NIH HHS / United States
R01 GM038511-12 / GM / NIGMS NIH HHS / United States
R01 GM058801-01 / GM / NIGMS NIH HHS / United States
R01 GM058801-10 / GM / NIGMS NIH HHS / United States
U54 CA112967-03 / CA / NCI NIH HHS / United States
U54 CA112967-04 / CA / NCI NIH HHS / United States
/ / Cancer Research UK / United Kingdom